natgillin/translations-raw huggingface dataset:
Rebif should be administered with caution to patients with previous or current depressive disorders in particular to those with antecedents of suicidal ideation (see section 4.3). 
Zdravilo Rebif moramo uporabljati previdno pri bolnikih, ki so imeli ali imajo trenutno depresivne bolezni, zlasti pri tistih s predhodnimi samomorilnimi mislimi (glejte poglavje 4.3).
Safety and efficacy with Rebif have not been demonstrated beyond 4 years of treatment. 
Varnost in učinkovitost zdravljenja z zdravilom Rebif, ki traja več kot štiri leta, nista dokazani.
• Irregularities and/or changes in menstrual flow 
• nerednem in/ali spremenjenem menstruacijskem ciklusu
The precise incidence of antibodies is as yet uncertain. 
Natančna incidenca pojava protiteles še ni znana.
• Liver inflammation (hepatitis) 
• vnetje jeter (hepatitis)
Clinical studies indicate that multiple sclerosis patients can receive Rebif and corticosteroids or ACTH during relapses. 
Klinične študije kažejo, da bolniki z multiplo sklerozo pri relapsu lahko prejemajo zdravilo Rebif skupaj s kortikosteroidi ali ACTH.
What Rebif is and what it is used for What you need to know before you use Rebif How to use Rebif 
Kaj je zdravilo Rebif in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Rebif Kako uporabljati zdravilo Rebif Možni neželeni učinki
This medicine is for multidose use. 
To zdravilo je za večkratno odmerjanje.
• The first injection(s) must be performed under the supervision of an appropriately qualified healthcare professional. 
• Dajanje prve injekcije (injekcij) mora biti izvedeno pod nadzorom ustrezno usposobljene zdravstvene osebe.
Over 4 years, the reduction in the mean exacerbation rate was 22% in patients treated with Rebif 22 micrograms, and 29% in patients treated with Rebif 44 micrograms group compared with a group of patients treated with placebo for 2 years and then either Rebif 22 or Rebif 44 micrograms for 2 years. 
Tekom 4 let se je povprečna pogostnost zagonov zmanjšala za 22 % pri bolnikih, ki so prejemali zdravilo Rebif 22 mikrogramov, in za 29 % pri bolnikih, ki so prejemali zdravilo Rebif 44 mikrogramov, v primerjavi s skupino bolnikov, ki so 2 leti prejemali placebo in nato še 2 leti zdravilo Rebif 22 mikrogramov ali zdravilo Rebif 44 mikrogramov.
If you are uncertain about the benefits, please consult your doctor. 
Če niste prepričani o koristih, se posvetujte z zdravnikom.
Rebif is available in three strengths: 8.8 micrograms, 22 micrograms and 44 micrograms. 
Zdravilo Rebif je na voljo v treh jakostih: 8,8 mikrogramov, 22 mikrogramov in 44 mikrogramov.
Rebif has not yet been investigated in patients with primary progressive multiple sclerosis, and should not be used in these patients. 
Zdravilo Rebif še ni bilo raziskano pri bolnikih s primarno progresivno multiplo sklerozo, zato se ga pri teh bolnikih ne sme uporabljati.
During the injection, the button will flash with a green light. 
Med injiciranjem gumb utripa z zeleno lučko.
Prompt treatment of nephrotic syndrome is required and discontinuation of treatment with Rebif should be considered. 
V primeru nefrotskega sindroma je potrebno takojšnje zdravljenje; razmisliti pa je treba tudi o prenehanju zdravljenja z zdravilom Rebif.
Rebif contains benzyl alcohol 
Zdravilo Rebif vsebuje benzilalkohol
Metabolism Interferon beta-1a is mainly metabolised and excreted by the liver and the kidneys. 
Presnova Interferon beta-1a se v glavnem presnavlja in izloča skozi jetra in ledvice.
From the fifth week onwards, after you have completed your initiation period, you will follow the usual dose regimen. 
Od petega tedna naprej, ko boste zaključili uvajalno obdobje, boste sledili običajnemu režimu odmerjanja.
These should be more frequent when initiating Rebif 44 micrograms. 
Testi morajo biti pogostejši pri uvajanju zdravljenja z zdravilom Rebif 44 mikrogramov.
• NOTE: From the fifth week onwards, after you have completed your initiation period, 0.5 mL (corresponding to the usual dose) should be selected in the dose window of the device. 
• OPOMBA: Od petega tedna naprej, ko končate začetno obdobje, izberite v oknu za odmerek pripomočka 0,5 ml (kar ustreza običajnemu odmerku).
th week 
- 2. teden
• Flu-like symptoms, such as headache, fever, chills, muscle and joint pains, fatigue and nausea are very common (may affect more than 1 in 10 people). 
• Gripi podobni simptomi, kot so glavobol, zvišana telesna temperatura, mrzlica, bolečine v mišicah in sklepih, utrujenost in siljenje na bruhanje, so zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov).
The administration of interferons has been associated with anorexia, dizziness, anxiety, arrhythmias, vasodilation and palpitation, menorrhagia and metrorrhagia. 
Uporabo interferonov povezujejo z anoreksijo, omotico, anksioznostjo, aritmijami, vazodilatacijo in palpitacijo, menoragijo in metroragijo.
• Injection site reactions including redness, swelling, discoloration, inflammation, pain and skin breakdown are very common. 
• Reakcije na mestu injiciranja, vključno z rdečico, oteklino, obarvanostjo kože, vnetjem, bolečino in razpokanjem kože, so zelo pogoste.
• When you do this please read carefully and follow the “RebiDose Instructions for Use” provided separately in the booklet. 
• Ko ste to storili, natančno preberite in upoštevajte » Navodila za uporabo peresnika RebiDose«, ki so priložena ločeno, v knjižici.
Rebif can be used during breastfeeding. 
Zdravilo Rebif se lahko uporablja med dojenjem.
Blood and the lymphatic system disorders Very common: 
Bolezni krvi in limfatičnega sistema Zelo pogosti:
Thyroid dysfunction, most often presenting as hypothyroidism or hyperthyroidism 
motnje delovanja ščitnice, najpogosteje v obliki hipotireoidizma ali hipertireoidizma
Rebif is a highly purified soluble protein that is similar to the natural interferon beta that is produced in the human body. 
Zdravilo Rebif je visoko prečiščena topna beljakovina, ki je podobna naravnemu interferonu beta, ki ga proizvaja človeško telo.
• Place RebiSmart at a right angle (90°) to the skin. 
• Namestite RebiSmart pod pravim kotom (90°) na kožo.
These symptoms are usually mild, are more common at the start of the treatment and decrease with continued use. 
Ti simptomi so običajno blagi in pogostejši na začetku zdravljenja, z nadaljnjo uporabo pa se zmanjšujejo.
It must not be given to premature babies or neonates. 
Uporaba pri nedonošenčkih ali novorojenčkih ni dovoljena.
In clinical trials, this was characterised by two or more acute exacerbations in the previous two years (see section 5.1). 
V kliničnih preskušanjih je bilo to opredeljeno z dvema ali več akutnimi zagoni bolezni v obdobju zadnjih dveh let (glejte poglavje 5.1).
The presence of antibodies has been shown to attenuate the pharmacodynamic response to interferon beta-1a (beta-2 microglobulin and neopterin). 
Pokazalo se je, da prisotnost protiteles slabi farmakodinamični odziv na interferon beta-1a (beta-2 mikroglobulin in neopterin).
Patients with poor vision should not use RebiSlide unless someone with good eyesight can provide support. 
Slabovidni bolniki ne smejo uporabljati pripomočka RebiSlide, razen če jim pomaga oseba, ki nima težav z vidom.
Hold the syringe like a pencil or dart. 
Injekcijsko brizgo primite kot svinčnik ali puščico.
If a second clinical demyelinating event occurred confirming definite multiple sclerosis, patients switched to the recommended posology of Rebif 44 micrograms three times per week in an open label manner, while maintaining blinding as to initial randomisation. 
Če je še drugi klinični dogodek z demielinizacijo potrdil dokončno multiplo sklerozo, so začeli bolnika zdraviti s priporočenim odmerjanjem zdravila Rebif 44 mikrogramov trikrat na teden z odprto oznako, vendar ob ohranitvi zaslepitve kot na začetku randomizacije.
Your doctor will advise you on the possible injection sites (good sites include the upper thighs and the lower abdomen). 
Vaš zdravnik vas bo podučil o možnih mestih za injiciranje (dobra mesta vključujejo zgornji del beder in spodnji del trebuha).
• Once you have finished your injection, immediately discard RebiDose. 
• Ko ste končali z injiciranjem, takoj zavrzite peresnik RebiDose.
• Drug-induced lupus erythematosus: a side-effect of long-term use of Rebif. 
• eritematozni lupus zaradi zdravila: neželeni učinek dolgotrajnega zdravljenja z zdravilom Rebif.
In a 3-year study in patients with secondary progressive multiple sclerosis (EDSS 3-6.5) with evidence of clinical progression in the preceding two years and who had not experienced relapses in the preceding 8 weeks, Rebif had no significant effect on progression of disability, but relapse rate was reduced by approximately 30%. 
V 3 letni študiji z bolniki, ki imajo sekundarno progresivno multiplo sklerozo (EDSS 3 do 6,5) s potrjenim kliničnim napredovanjem bolezni v predhodnih dveh letih in brez zagonov v predhodnih osmih tednih, zdravilo Rebif ni imelo pomembnega učinka na napredovanje nesposobnosti, vendar pa je zmanjšalo delež zagonov bolezni za približno 30 %.
It will also instruct you when you need to change the cartridge. 
Dal vam bo tudi navodila o tem, kako zamenjati vložek.
Severe renal or hepatic failure and severe myelosuppression 
Hudo ledvično ali jetrno odpovedovanje in huda mielosupresija
If there are particles or other visible signs of deteriorations, do not use it and contact your doctor, nurse or pharmacist for assistance. 
Če opazite delce ali druge vidne znake kvarjenja, ga ne uporabite in se po pomoč obrnite na svojega zdravnika, medicinsko sestro ali farmacevta.
Treatment with Rebif should be stopped if icterus or other clinical symptoms of liver dysfunction appear. 
Zdravljenje z zdravilom Rebif moramo ukiniti, če se pojavi zlatenica ali drugi klinični znaki motenj v delovanju jeter.
Neutropenia, lymphopenia, leukopenia, thrombocytopenia, anaemia 
nevtropenija, limfopenija, levkopenija, trombocitopenija, anemija
The safety and efficacy of Rebif has been evaluated in patients with relapsing-remitting multiple sclerosis at doses ranging from 11 to 44 micrograms (3-12 million IU), administered subcutaneously three times per week. 
Varnost in učinkovitost zdravila Rebif je bila ocenjena pri bolnikih z recidivno-remitentno multiplo sklerozo, pri odmerkih v razponu od 11 do 44 mikrogramov (3-12 milijonov i.e.), podkožno trikrat na teden.
Tissue destruction (necrosis), abscess and mass at injection site are uncommon (may affect up to 1 in 100 people). 
Razgradnja tkiva (nekroza), abscesi in bule se na mestu injiciranja pojavljajo občasno (pojavijo se lahko pri največ 1 od 100 bolnikov).
Thyroid function testing is recommended at baseline and if abnormal, every 6-12 months following initiation of therapy. 
Preiskave delovanja ščitnice se priporoča na začetku zdravljenja in, če so rezultati abnormalni, vsakih 6 do 12 mesecev od začetka zdravljenja.
Rebif should be administered with caution to patients with a history of seizures, to those receiving treatment with anti-epileptics, particularly if their epilepsy is not adequately controlled with antiepileptics (see sections 4.5 and 4.8). 
Zdravilo Rebif moramo uporabljati previdno pri bolnikih, ki so imeli v preteklosti epileptične napade, ter pri bolnikih, ki se zdravijo z antiepileptiki, zlasti pri tistih, kjer napadov ni bilo mogoče zadovoljivo kontrolirati z antiepileptiki (glejte poglavji 4.5 in 4.8).
Weeks 3-4 
3. in 4. teden
Rebif is used for the treatment of multiple sclerosis. 
Zdravilo Rebif se uporablja za zdravljenje multiple skleroze.
The highest incidence of adverse reactions associated with Rebif therapy is related to flu-like syndrome. 
Največja incidenca neželenih učinkov v zvezi z zdravljenjem z zdravilom Rebif je povezana z gripi podobnimi simptomi.
Your doctor has prescribed you a lower dose of 22 micrograms (6 million IU) given three times per week. 
Vaš zdravnik vam je predpisal nižji odmerek 22 mikrogramov (6 milijonov i.e.) trikrat na teden.
After the injection of Rebif with either RebiSmart or RebiSlide 
Po injiciranju zdravila Rebif bodisi s pripomočkom Rebismart ali Rebislide
Patients should be informed of the most frequent adverse reactions associated with interferon beta administration, including symptoms of the flu-like syndrome (see section 4.8). 
Bolnik mora biti seznanjen z najbolj pogostimi neželenimi učinki, povezanimi z uporabo interferona beta, vključno s simptomi gripi podobnega sindroma (glejte poglavje 4.8).
No information is available on the effects of the interferon beta-1a on male fertility. 
Ni podatkov o učinku interferona beta-1a na moško plodnost.
•Talk to your doctor or pharmacist before taking Rebif if you have an allergy (hypersensitivity) to any other medicines. 
• Pred začetkom uporabe zdravila Rebif se posvetujte z zdravnikom ali farmacevtom, če imate alergijo (ste preobčutljivi) na katero koli zdravilo.
If there is liquid left, not all of the medicine has been injected and you should consult your doctor or nurse for assistance. 
Če vidite ostanek tekočine, to pomeni, da ni bila injicirana celotna količina zdravila, zato se po pomoč obrnite na svojega zdravnika ali medicinsko sestro.
Talk to your doctor if you experience any of the following side effects: 
Posvetujte se z zdravnikom, če se pojavi kateri od teh neželenih učinkov:
The first injection(s) must be performed under the supervision of an appropriately qualified healthcare professional. 
Dajanje prve injekcije (injekcij) mora biti izvedeno pod nadzorom ustrezno usposobljene zdravstvene osebe.
If you use more Rebif than you should In case of overdose, contact your doctor immediately. 
Če ste uporabili večji odmerek zdravila Rebif, kot bi smeli V primeru prekoračenega odmerka se takoj posvetujte z zdravnikom.
• Before the injection, use an alcohol wipe to clean the skin at the injection site. 
• Pred injiciranjem uporabite za čiščenje kože na mestu injiciranja alkoholno blazinico.
Symptoms of the flu-like syndrome associated with interferon beta-1a therapy may prove stressful to patients with cardiac conditions. 
Znaki gripi podobnega sindroma, ki so povezani z zdravljenjem z interferonom beta-1a, lahko stresno vplivajo na srčne bolnike.
E. Main body F. Button 
D. nalepka E. osrednji del F. gumb
The proportion of patients with disability progression, as defined by at least one point increase in EDSS confirmed three months later, was reduced from 39% (placebo) to 27% (Rebif 44 micrograms). 
Odstotek bolnikov z napredovanjem nesposobnosti, definiranim kot povečanje za najmanj eno točko po EDSS, potrjenim po 3 mesecih, se je zmanjšal iz 39 % (placebo) na 27 % (zdravilo Rebif 44 mikrogramov).
After a single dose, intracellular and serum activity of 2'5'OAS synthetase and serum concentrations of beta-2 microglobulin and neopterin increase within 24 hours, and start to decline within 2 days. 
Po enkratnem odmerku se v 24 urah povečajo intracelularna in serumska aktivnost 2-5A sintetaze in serumske koncentracije beta-2 mikroglobulina ter neopterina in pričnejo upadati v 2 dneh.
Only clear to opalescent solution without particles and without visible signs of deterioration should be used. 
Biti mora bister do opalescenten, brez delcev in vidnih znakov kvarjenja.
• Kidney problems including scarring that may reduce your kidney function. 
• Težave z ledvicami, vključno z brazgotinjenjem, lahko zmanjšajo delovanje ledvic.
Rebif solution for subcutaneous injection in a cartridge is intended for multidose use with either the RebiSmart electronic injection device or the RebiSlide manual pen-injector device following adequate training of the patient and/or carer. 
Zdravilo Rebif raztopina za subkutano injiciranje v vložku je namenjeno za večkratno odmerjanje, bodisi z elektronskim pripomočkom za injiciranje RebiSmart ali z ročnim injekcijskim peresnikom RebiSlide, po ustreznem izobraževanju bolnika in/ali negovalca.
Rebif, like other interferons beta, has a potential for causing severe liver injury including acute hepatic failure (see section 4.8). 
Zdravilo Rebif ima, tako kot drugi interferoni beta, potencial za povzročanje hudih jetrnih poškodb, vključno z akutno jetrno odpovedjo (glejte poglavje 4.8).
In healthy volunteers after intravenous administration, interferon beta-1a exhibits a sharp multi-exponential decline, with serum levels proportional to the dose. 
Pri zdravih prostovoljcih se po intravenskem dajanju interferona beta-1a pokaže oster multieksponentni padec serumskih vrednosti, sorazmerno z odmerkom.
Other forms of multiple sclerosis 
Druge oblike multiple skleroze
Rebif is indicated for the treatment of 
Zdravilo Rebif je indicirano za zdravljenje
• a dry cotton ball or gauze 
• suh kos bombažne vate ali gaze
When first starting treatment with Rebif, the dose should be gradually escalated in order to allow tachyphylaxis to develop thus reducing adverse reactions. 
Na začetku prvega zdravljenja z zdravilom Rebif se odmerek postopno viša z namenom razvoja tahifilaksije in s tem zmanjšanja neželenih učinkov.
Rebif solution is clear to opalescent. 
Raztopina Rebif je bistra do opalescentna.
• Keep track of and rotate your injection sites, so that one area is not injected too often. 
• Beležite si mesta injiciranja in jih izmenjujte tako, da ne zabadate prepogosto v eno in isto mesto.
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome* (class label for interferon beta products, see section 4.4), pancytopenia* 
trombotična mikroangiopatija, vključno s trombotično trombocitopenično purpuro/hemolitično-uremičnim sindromom * (označevanje razreda zdravil, ki vsebujejo interferon beta; glejte poglavje 4.4), pancitopenija*
Patients were randomised in a double-blind manner to either Rebif 44 micrograms given three times per week, Rebif 44 micrograms once weekly, or placebo. 
Bolniki so bili randomizirani na dvojno slep način v bodisi skupino, ki je prejemala zdravilo Rebif 44 mikrogramov trikrat na teden, v skupino, ki je prejemala zdravilo Rebif 44 mikrogramov enkrat na teden, ali v skupino, ki je prejemala placebo.
Severe elevations in transaminases 
močno zvišanje ravni transaminaz
Patients being treated with Rebif may occasionally develop new or worsening thyroid abnormalities. 
Pri bolnikih, ki se zdravijo z zdravilom Rebif, se lahko občasno razvijejo ali pa poslabšajo motnje delovanja ščitnice.
• Read all the following instructions carefully before using RebiDose. 
• Pred uporabo peresnika RebiDose natančno preberite naslednja navodila.
The proportion of patients with disability progression, as defined by at least one point increase in EDSS confirmed three months later, was reduced from 39% (placebo) to 30% (Rebif 22 micrograms). 
Odstotek bolnikov z napredovanjem nesposobnosti, definiranim kot povečanje za najmanj eno točko po EDSS, potrjenim po 3 mesecih, se je zmanjšal iz 39 % (placebo) na 30 % (zdravilo Rebif 22 mikrogramov).
• Hold RebiSlide firmly and slide the release button which is on the side of the device. 
• Trdno držite pripomoček RebiSlide in potisnite sprožilni gumb, ki je ob strani pripomočka.
Regardless of the route of dosing, pronounced pharmacodynamic changes are associated with the administration of Rebif. 
Neodvisno od poti odmerjanja so z uporabo zdravila Rebif povezane izrazite farmakodinamične spremembe.
If the patient experiences any break in the skin, which may be associated with swelling or drainage of fluid from the injection site, the patient should be advised to consult with their physician before continuing injections with Rebif. 
Bolniku moramo svetovati, da se v primeru pojava kakršne koli razpoke v koži, ki jo lahko spremlja oteklina ali odtekanje tekočine iz mesta injiciranja, posvetuje s svojim zdravnikom, preden nadaljuje z uporabo injekcij zdravila Rebif.
Injection site cellulitis* 
celulitis na mestu injiciranja*
Before the injection 
Pred injiciranjem
Store in a refrigerator (2°C - 8°C) away from the cooling element. 
Shranjujte v hladilniku (2 ºC-8 ºC), stran od zamrzovalnega predela.
If you stop using Rebif 
Če ste prenehali uporabljati zdravilo Rebif
Frequency not known: Transient neurological symptoms (i.e. hypoesthesia, muscle spasm, paraesthesia, difficulty in walking, musculoskeletal stiffness) that may mimic multiple sclerosis exacerbations* 
prehodni nevrološki simptomi (npr. hipoestezija, mišični krči, parestezije, težave pri hoji in mišično-skeletna okorelost), ki so lahko podobni poslabšanju multiple skleroze*
It may cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old. 
Lahko povzroči toksične reakcije in anafilaktoidne reakcije pri dojenčkih in otrocih do 3 leta starosti.
• The active substance is interferon beta-1a. 
• Učinkovina je interferon beta-1a.
What Rebif looks like and contents of the pack 
Izgled zdravila Rebif in vsebina pakiranja
Frequency not known: Pulmonary arterial hypertension* (class label for interferon products, see below Pulmonary arterial hypertension) 
pljučna arterijska hipertenzija* (velja za skupino zdravil, ki vsebujejo interferone - glejte Pljučna arterijska hipertenzija spodaj)
If a patient responds poorly to therapy with Rebif, and has neutralising antibodies, the treating physician should reassess the benefit/risk ratio of continued Rebif therapy. 
Pri bolnikih, kjer je odziv na zdravljenje z zdravilom Rebif slab in so razvili protitelesa, mora lečeči zdravnik ponovno pretehtati razmerje koristi in tveganja pri nadaljevanju zdravljenja z zdravilom Rebif.
• Blood clots in the small blood vessels may occur during your treatment. 
• Med zdravljenjem se lahko pojavijo krvni strdki v majhnih krvnih žilah.
Peaks of similar height and time were observed for most of these markers after first and sixth administration. 
Za večino teh označevalcev so po prvem in šestem dajanju zdravila opazili podobne najvišje vrednosti, ki so se pojavile približno ob istem času.
Symptoms may include increased bruising, bleeding, fever, extreme weakness, headache, dizziness or light-headedness. 
Simptomi lahko vključujejo povečano nastajanje modric, krvavitve, povišano telesno temperaturo, izjemno šibkost, glavobol, omotico ali vrtoglavico.
This might happen several weeks to several years after starting Rebif. 
To se lahko pojavi nekaj tednov do nekaj let po začetku zdravljenja z zdravilom Rebif.
• thyroid, 
• ledvic,
If you forget to use Rebif 
Če ste pozabili uporabiti zdravilo Rebif
Injection site necrosis, injection site mass, injection site abscess, injection site infections*, increased sweating* 
nekroza na mestu injiciranja, bula na mestu injiciranja, absces na mestu injiciranja, okužbe na mestu injiciranja*, povečano potenje*
If you experience troubling local reactions, contact your doctor. 
Če se pojavijo moteče lokalne reakcije, se posvetujte z zdravnikom.
The safety guard automatically surrounds the needle and locks into place to protect you from the needle. 
Varovalo se samodejno povezne čez iglo in jo zaradi zaščite blokira.
Weeks 1-2 
• 1. in 2. teden
OTHER Merck Europe B.V. 
DRUGI PODATKI Merck Europe B.V.
Asymptomatic transaminase increase 
asimptomatsko zvečanje ravni transaminaz
Laboratory abnormalities are associated with the use of interferons. 
Z uporabo interferonov so povezani nenormalni laboratorijski testi.
You should discuss this with your doctor if you are concerned. 
Če ste zaskrbljeni, se o tem posvetujte s svojim zdravnikom.
• Disorders of the retina (back of the eye) such as inflammation or blood clots with consequent vision disorders (vision disturbances, loss of vision) 
• bolezni mrežnice (očesnega ozadja), kot so vnetje ali krvni strdki s posledičnimi motnjami vida
Retinal vascular disorders (i.e. retinopathy, cotton wool spots, obstruction of retinal artery or vein)* 
bolezni mrežničnega žilja (npr. retinopatija, pojav belih lis na mrežnici in zamašitev mrežnične arterije ali vene)*
• Remove and discard the needle according to the instruction manual provided with your device. 
• Iglo odstranite in zavrzite v skladu z navodili za uporabo v priročniku, ki je priložen vašemu pripomočku.
The recommended posology of Rebif is 44 micrograms given three times per week by subcutaneous injection. 
Priporočeno odmerjanje zdravila Rebif je 44 mikrogramov, trikrat na teden v obliki subkutane injekcije.